Don't expect GSK to spin off ViiV anytime soon

GlaxoSmithKline ($GSK) may have sequestered its HIV drugs and development in a joint venture with Pfizer ($PFE), ViiV Healthcare. But that doesn't mean the U.K.-based drugmaker intends to spin off the business. Not now, at least. "ViiV exists as a standalone company of which we are majority shareholders," GSK president of pharma R&D, Patrick Vallance, told Bloomberg. Handing over all its HIV work to ViiV, Valance said, has "provided a huge focus around the HIV space, and it's been an interesting lesson for GSK about how to get that sort of focus." Story